Is there still any hope for amyloid-based immunotherapy for Alzheimerʼs disease?
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Is there still any hope for amyloid-based immunotherapy for Alzheimerʼs disease?
Authors
Keywords
-
Journal
CURRENT OPINION IN PSYCHIATRY
Volume 27, Issue 2, Pages 128-137
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2014-01-21
DOI
10.1097/yco.0000000000000041
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 2013 Alzheimer's disease facts and figures
- (2013) Alzheimers & Dementia
- Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease
- (2013) Aaron H. Burstein et al. CLINICAL NEUROPHARMACOLOGY
- Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease
- (2013) Jaren W. Landen et al. CLINICAL NEUROPHARMACOLOGY
- Intravenous immunoglobulin and Alzheimer’s disease: what now?
- (2013) David A Loeffler Journal of Neuroinflammation
- Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial
- (2013) H. Davtyan et al. JOURNAL OF NEUROSCIENCE
- Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
- (2013) Richard Dodel et al. LANCET NEUROLOGY
- Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
- (2013) Victor L Villemagne et al. LANCET NEUROLOGY
- Immunotherapy for Alzheimer’s disease: hoops and hurdles
- (2013) Cynthia A Lemere Molecular Neurodegeneration
- Development of a New DNA Vaccine for Alzheimer Disease Targeting a Wide Range of Aβ Species and Amyloidogenic Peptides
- (2013) Yoh Matsumoto et al. PLoS One
- Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
- (2012) Martin Farlow et al. Alzheimers & Dementia
- Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease
- (2012) Henrik Zetterberg ARCHIVES OF NEUROLOGY
- Gantenerumab for the treatment of Alzheimer's disease
- (2012) Julien Delrieu et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease
- (2012) Bruno P Imbimbo et al. Expert Review of Clinical Immunology
- Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies
- (2012) Francesco Panza et al. Immunotherapy
- Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis
- (2012) Jungsu Kim et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Intranasal inoculation with an adenovirus vaccine encoding ten repeats of Aβ3-10 reduces AD-like pathology and cognitive impairment in Tg-APPswe/PSEN1dE9 mice
- (2012) Yu Li et al. JOURNAL OF NEUROIMMUNOLOGY
- An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A
- (2012) O. Adolfsson et al. JOURNAL OF NEUROSCIENCE
- Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
- (2012) Bengt Winblad et al. LANCET NEUROLOGY
- Active vaccination with ankyrin G reduces β-amyloid pathology in APP transgenic mice
- (2012) A C Santuccione et al. MOLECULAR PSYCHIATRY
- Genentech's Alzheimer's antibody trial to study disease prevention
- (2012) Ken Garber NATURE BIOTECHNOLOGY
- Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model
- (2012) Jose Morales-Corraliza et al. NEUROBIOLOGY OF AGING
- Passive Immunization against Pyroglutamate-3 Amyloid-ß Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study
- (2012) Jeffrey L. Frost et al. Neurodegenerative Diseases
- A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
- (2012) Ronald B. DeMattos et al. NEURON
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
- (2012) Randall J. Bateman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stopping Alzheimer's Before It Starts
- (2012) G. Miller SCIENCE
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
- (2011) Susanne Ostrowitzki ARCHIVES OF NEUROLOGY
- Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab
- (2011) Francesco Panza et al. Current Alzheimer Research
- Antibody-based therapy in Alzheimer's disease
- (2011) Refik Pul et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The Second-Generation Active A Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects
- (2011) C. Wiessner et al. JOURNAL OF NEUROSCIENCE
- The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia
- (2010) Jessica M. Mc Donald et al. BRAIN
- Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease
- (2010) Eric R. Siemers et al. CLINICAL NEUROPHARMACOLOGY
- Revising the definition of Alzheimer's disease: a new lexicon
- (2010) Bruno Dubois et al. LANCET NEUROLOGY
- 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
- (2010) Juha O Rinne et al. LANCET NEUROLOGY
- Alzheimer's disease: clinical trials and drug development
- (2010) Francesca Mangialasche et al. LANCET NEUROLOGY
- Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders
- (2009) Bruno Vellas et al. Current Alzheimer Research
- Disease-Modifying Approach to the Treatment of Alzheimerʼs Disease
- (2009) Francesco Panza et al. DRUGS & AGING
- Vaccination with A -Displaying Virus-Like Particles Reduces Soluble and Insoluble Cerebral A and Lowers Plaque Burden in APP Transgenic Mice
- (2009) P. Bach et al. JOURNAL OF IMMUNOLOGY
- Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing
- (2009) A. Schneeberger et al. Journal of Nutrition Health & Aging
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
- (2009) S. Salloway et al. NEUROLOGY
- Oligomeric amyloid associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques
- (2009) R. M. Koffie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- DNA epitope vaccine containing complement component C3d enhances anti-amyloid-β antibody production and polarizes the immune response towards a Th2 phenotype
- (2008) Nina Movsesyan et al. JOURNAL OF NEUROIMMUNOLOGY
- Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
- (2008) Clive Holmes et al. LANCET
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
- (2008) Ganesh M Shankar et al. NATURE MEDICINE
- Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse
- (2008) Peter Seubert et al. Neurodegenerative Diseases
- Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine — A Novel Immunotherapeutic Strategy
- (2008) Nina Movsesyan et al. PLoS One
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More